Tocilizumab stabilizes lung function in SSc-related interstitial lung disease

February 23, 2021

2 min read

Source/Disclosures

Published by:

Disclosures: Roofeh reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tocilizumab treatment in early interstitial lung disease, with progressive skin involvement related to systemic sclerosis, was able to stabilize forced vital capacity over 48 weeks, according to data published in Arthritis & Rheumatology.

“The majority of systemic sclerosis patients will develop interstitial lung disease (SSc-ILD),” David Roofeh, MD, of the University of Michigan, and colleagues wrote. “Those at risk for progressive disease have an archetype: Early, diffuse cutaneous systemic sclerosis (dcSSc), with elevated acute phase reactants like C-reactive protein (CRP) and topoisomerase-1 antibody positivity…

Want to know more click here go to source.

From Healio - February 23, 2021